NP-011
/ Nexel
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
July 30, 2023
A Promising Novel Therapeutic Strategy for Inflammatory Bowel Disease Through Enhanced Efferocytosis and Anti-Inflammatory Mechanisms
(ACG 2023)
- "NP-011 demonstrated strong affinity to phosphatidylserine (PS) and boosted the uptake of PS and apoptotic cells (ACs) by macrophages, leading to an enhanced expression of HO-1. The maximum count of TUNEL-positive cells in mouse colons was observed on day five post-exposure to DSS. By strategically administering NP-011 on this pivotal day, we managed to effectively reduce the count of ACs, and lower the concentration of inflammation and necrosis markers in the blood."
Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis
August 03, 2023
A Study of NP-011 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=64 | Completed | Sponsor: Nexel Co., Ltd. | Active, not recruiting ➔ Completed
Trial completion • Cardiovascular • Myocardial Infarction
March 29, 2023
A Study of NP-011 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=64 | Active, not recruiting | Sponsor: Nexel Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Jan 2023 ➔ May 2023 | Trial primary completion date: Nov 2022 ➔ Mar 2023
Enrollment closed • Trial completion date • Trial primary completion date • Cardiovascular • Myocardial Infarction
September 28, 2022
A Study of NP-011 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=64 | Recruiting | Sponsor: Nexel Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Cardiovascular • Myocardial Infarction
June 04, 2022
NEXEL
(BIO 2022)
- "Our protein/Peptide therapy pipelines, NP-011 and NPT-0025, were designed by remodeling a protein found in embryonic stem cell secretomes. NEXEL is a specialist in the differentiation of human iPSC, having successfully developed several off-the-shelf products such as cardiomyocytes, hepatocytes, and neurons. hiPSC-derived cells are proving to be an excellent in vitro model to potentially revolutionize preclinical drug toxicity testing, as evidenced by upcoming ICH guideline changes(S7B) with CiPA."
Fibrosis • Hepatology • Immunology • Non-alcoholic Steatohepatitis
1 to 5
Of
5
Go to page
1